ABLYNX ANNOUNCES WARRANT EXERCISE
February 23, 2016 01:09 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Feb. 23, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and the...
ABLYNX WILL ANNOUNCE ITS 2015 FULL YEAR RESULTS WITH WEBCAST ON 25 FEBRUARY 2016
February 18, 2016 01:11 ET
|
Ablynx
GHENT, Belgium, Feb. 18, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will announce its full year results for 2015 on Thursday 25 February 2016 at 7.00 am CET.
The Ablynx...
NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES ABLYNX'S PHASE II TITAN STUDY OF CAPLACIZUMAB IN PATIENTS WITH ACQUIRED TTP
February 11, 2016 01:17 ET
|
Ablynx
Proof-of-concept in the Phase II TITAN study was achieved with significant reductions in time to platelet count normalisation and recurrences while on treatment with caplacizumab
Based on...
ABLYNX TO RECEIVE EU8 MILLION MILESTONE AS BOEHRINGER INGELHEIM STARTS FIRST PATIENT STUDY WITH A BI-SPECIFIC NANOBODY IN ONCOLOGY
January 29, 2016 01:06 ET
|
Ablynx
GHENT/ZWIJNAARDE, Belgium, Jan. 29, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that Boehringer Ingelheim has administered the first dose in a Phase I dose...
ABLYNX ANNOUNCES WARRANT EXERCISE
January 21, 2016 01:05 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Jan. 21, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in conformity with Title II of the Law of 2 May 2007 and...
PERCEPTIVE ADVISORS LLC ANNOUNCE 5.06% SHAREHOLDING IN ABLYNX
January 18, 2016 01:19 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Jan. 18, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007...
ABLYNX TO PRESENT AT THE 34th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
January 07, 2016 01:04 ET
|
Ablynx
GHENT, Belgium, Jan. 7, 2016 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that it will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday 14...
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
January 05, 2016 01:07 ET
|
Ablynx
REGULATED...
PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
December 22, 2015 01:10 ET
|
Ablynx
REGULATED INFORMATION
GHENT, Belgium, Dec. 22, 2015 (GLOBE NEWSWIRE) -- Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May...
ABLYNX COMPLETES ENROLMENT OF THE FIRST-IN-INFANT PHASE I/IIa SAFETY STUDY WITH ITS ANTI-RSV NANOBODY AND EXTENDS THE TRIAL FOR YOUNGER INFANTS
December 17, 2015 01:05 ET
|
Ablynx
Target enrolment of 35 infants, aged 3-24 months, completed
On track to release top line results in the first half of 2016
Study extended for infants aged 1-5 months
GHENT, Belgium,...